NO974956L - Therapeutic composition for arthritis - Google Patents
Therapeutic composition for arthritisInfo
- Publication number
- NO974956L NO974956L NO974956A NO974956A NO974956L NO 974956 L NO974956 L NO 974956L NO 974956 A NO974956 A NO 974956A NO 974956 A NO974956 A NO 974956A NO 974956 L NO974956 L NO 974956L
- Authority
- NO
- Norway
- Prior art keywords
- arthritis
- agent
- administration
- inflammatory
- acting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Det blir fremskaffet et farmasøytisk middel som viser hurtigvirkende og vedvarende anti-inflammatorisk analgesisk virkning mot kronisk artritis med lav fremtreden av bieffekter. En farmasøytisk sammensetning omfattende en kombinasjon av et quinolin-/quina- zolinserier profylaktisk/terapeutisk middel for artritis og hurtigvirkende anti-inflam- matorisk analgesisk middel omfattende (1) en cyklooksygenaseinhibitor, (2) et sentralt analgesika, (3) et steroid eller (4) et anti-inflammatorisk enzym-middel. Foreliggende preparat viser utmerkede effekter mot artritis fra administrasjon for å sikre stabil anti-inflammatorisk analgesisk virkning med lav fremtreden av bieffekter selv ved kronisk administrasjon, forutsatt at medikamentsammensetning, administrasjonsmetode og dose er passende valgt ifølge symptomene.A pharmaceutical agent is provided which shows fast-acting and sustained anti-inflammatory analgesic action against chronic arthritis with a low onset of side effects. A pharmaceutical composition comprising a combination of a quinoline / quinazoline series prophylactic / therapeutic agent for arthritis and fast-acting anti-inflammatory analgesic agent comprising (1) a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid or ( 4) an anti-inflammatory enzyme agent. The present preparation shows excellent effects against arthritis from administration to ensure stable anti-inflammatory analgesic effect with low appearance of side effects even in chronic administration, provided that drug composition, administration method and dose are appropriately selected according to the symptoms.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10631695 | 1995-04-28 | ||
JP27085695 | 1995-10-19 | ||
PCT/JP1996/001102 WO1996033717A1 (en) | 1995-04-28 | 1996-04-24 | Therapeutic composition for arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
NO974956L true NO974956L (en) | 1997-10-27 |
NO974956D0 NO974956D0 (en) | 1997-10-27 |
Family
ID=26446436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO974956A NO974956D0 (en) | 1995-04-28 | 1997-10-27 | Therapeutic composition for arthritis |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0830133A1 (en) |
KR (1) | KR19990008148A (en) |
AU (1) | AU715358B2 (en) |
CA (1) | CA2216138A1 (en) |
HU (1) | HUP9801628A2 (en) |
NO (1) | NO974956D0 (en) |
WO (1) | WO1996033717A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262269B1 (en) | 1997-02-04 | 2001-07-17 | Trega Biosciences, Inc. | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries |
AU8191998A (en) * | 1997-02-04 | 1998-08-25 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
JP3930428B2 (en) | 2000-08-09 | 2007-06-13 | エフ.ホフマン−ラ ロシュ アーゲー | Quinoline derivatives as anti-inflammatory agents |
CA2436739A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68908459T2 (en) * | 1988-04-26 | 1994-04-07 | Asahi Glass Co Ltd | Prepolymer composition, process for its preparation and its use. |
US4968701A (en) * | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
US5187180A (en) * | 1990-07-26 | 1993-02-16 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
IE920499A1 (en) * | 1991-02-21 | 1992-08-26 | Merck Frosst Canada Inc | Quinoline-containing ketoacids as leukotriene antagonists |
TW232013B (en) * | 1992-04-24 | 1994-10-11 | Takeda Pharm Industry Co Ltd | |
NO940245D0 (en) * | 1993-01-28 | 1994-01-24 | Takeda Chemical Industries Ltd | Quinoline or quinazoline derivatives, their preparation and use |
US5641788A (en) * | 1994-06-07 | 1997-06-24 | Takeda Chemical Industries, Ltd. | Quinoline derivatives and pharmaceutical composition containing them |
-
1996
- 1996-04-24 EP EP96912213A patent/EP0830133A1/en not_active Withdrawn
- 1996-04-24 WO PCT/JP1996/001102 patent/WO1996033717A1/en not_active Application Discontinuation
- 1996-04-24 AU AU55136/96A patent/AU715358B2/en not_active Ceased
- 1996-04-24 HU HU9801628A patent/HUP9801628A2/en unknown
- 1996-04-24 KR KR1019970707673A patent/KR19990008148A/en not_active Application Discontinuation
- 1996-04-24 CA CA002216138A patent/CA2216138A1/en not_active Abandoned
-
1997
- 1997-10-27 NO NO974956A patent/NO974956D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996033717A1 (en) | 1996-10-31 |
AU715358B2 (en) | 2000-01-20 |
AU5513696A (en) | 1996-11-18 |
HUP9801628A2 (en) | 1999-01-28 |
EP0830133A1 (en) | 1998-03-25 |
NO974956D0 (en) | 1997-10-27 |
CA2216138A1 (en) | 1996-10-31 |
KR19990008148A (en) | 1999-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1637A (en) | Celecoxib compositions. | |
BR0013704A (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases | |
NO922004D0 (en) | ORAL PREPARATION FOR TREATMENT OF INFLAMMATORY GAS DISORDERS | |
NO305537B1 (en) | Pharmaceutical preparation containing a defined lipid system and use of the lipid system | |
BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
SE9704870D0 (en) | New pharmaceutical formulation I | |
ATE486840T1 (en) | MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF | |
WO1998019649A3 (en) | Methods and compositions for inhibition of angiogenesis | |
RO116342B1 (en) | Oral liquid pharmaceutical composition | |
BR9709838A (en) | Administration regimen that provides a blood plasma profile of an h +, k + -atpase inhibitor oral pharmaceutical composition and the use of h +, k + -atpase inhibitor and processes to improve the inhibition of gastric acid secretion and the therapeutic effect on treatment of gastrointestinal disorders and to receive an extended plasma profile of an h +, k + -atpase inhibitor | |
MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
BR9810520A (en) | Factor xa inhibitor alone or in combination with an anti-platelet aggregator, against arterial thrombosis | |
WO2000033790A3 (en) | Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs | |
BR9813179A (en) | Extended release formulation | |
ES2193233T3 (en) | USE OF AMIODIPINE, A SALT OF THE SAME OR PHELODIPINE IN COMBINATION WITH AN ACE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ISCHEMICAL CONJUNCTIVE HEART FAILURE. | |
ES2126123T3 (en) | USE OF CINEOL OR MENTHOL FOR THE TREATMENT OF ASTHMA. | |
BR9803233A (en) | Preparation of a pharmaceutical combination of a sodium / hydrogen exchanger inhibitor and a drug for the treatment of cardiovascular diseases. | |
NO974956L (en) | Therapeutic composition for arthritis | |
NO955084L (en) | Estreno steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | |
NO990450L (en) | Treatment of mental disorders | |
DK0862454T3 (en) | CTLA-8 in combination with G-CSF or with G-CSF and IL-6 and use of CTLA-8 to treat infections | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
BR0012121A (en) | Aminotetralin derivative for cardiovascular disease therapy | |
NO952234L (en) | Transdermal administration system containing acetylsalicylic acid for antithrombosis therapy and cancer prevention | |
NO20050933L (en) | Pravastatin pharmaceutical formulations and methods for their use |